Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ramulus mori refers to the dried twigs of Morus alba (white mulberry), widely used in Traditional Chinese Medicine (TCM) under the name "sangzhi." It is a botanical drug with a rich profile of bioactive compounds including alkaloids (notably polyhydroxy alkaloids such as 1-deoxynojirimycin, fagomine, and DAB), flavonoids, polysaccharides, coumarins, phenolic acids, stilbenes (e.g., resveratrol), and amino acids[2][3][6]. Ramulus mori and its extracts are approved in China for use as hypoglycemic agents—specifically for type 2 diabetes mellitus—due to their potent inhibition of α-glucosidase enzymes in the gut. This leads to reduced postprandial blood glucose levels by delaying carbohydrate absorption[1][2][4]. Additional pharmacological effects include improvement in lipid metabolism and insulin secretion; anti-inflammatory activity; modulation of gut microbiota; diuretic effects; relief from edema; and potential benefits for obesity-related metabolic disorders[5][6]. In TCM practice it is also used for gout, arthritis, rheumatism, asthma therapy and as an antirheumatic agent[6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ramulus mori.